Page last updated: 2024-12-08

inositol 4-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

inositol 4-phosphate: RN given refers to (DL-myo)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID440043
CHEBI ID166491
CHEBI ID18384
SCHEMBL ID1331533
SCHEMBL ID16345949
MeSH IDM0132352

Synonyms (23)

Synonym
[(2r,3s,5s,6s)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate
CHEBI:166491
1d-myo-inositol 4-(dihydrogen phosphate)
CHEBI:18384
inositol 4-phosphate
C03546
d-myo-inositol 4-phosphate
myo-inositol 4-phosphate
D-MYO-INOSITOL-4-PHOSPHATE ,
1d-myo-inositol 4-monophosphate
1d-myo-inositol 4-phosphate
SCHEMBL1331533
{[(1s,2r,3s,4s,5s,6s)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphonic acid
gtpl5205
d-myo-inositol-4-hydrogen phosphate
INAPMGSXUVUWAF-CNWJWELYSA-N
SCHEMBL16345949
d-myoinositol 4-phosphate
(1s,2r,3s,4s,5s,6s)-2,3,4,5,6-pentahydroxycyclohexyl dihydrogen phosphate
Q27078076
CS-0226141
d-myo-inositol 4-mono-phos-phate
HY-W145699

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
inositol phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Inositol phosphate metabolism3235
Synthesis of IP2, IP, and Ins in the cytosol517
Inositol phosphate metabolism ( Inositol phosphate metabolism )4218

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (38.89)18.7374
1990's9 (50.00)18.2507
2000's1 (5.56)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]